24 January 2019 | News
B-MoGen's genetic engineering expertise together with CytoSen's NK Cell stimulation platform seeks to build the next generation of NK cell cancer therapeutics
B-MoGen Biotechnologies, Inc. and CytoSen Therapeutics have announced a research collaboration to develop the next generation of gene-modified Natural Killer Cell (NK) therapies. B-MoGen will utilize its expertise in genetic design and its patented non-viral gene delivery platform in conjunction with CytoSen's nanoparticle expansion platform to improve efficacy and reduce cost of NK cell therapeutics.
"We are very excited and look forward to teaming up with CytoSen to utilize our scientific expertise and engineering work with CARs and TCRs to help develop NK treatments in the human therapeutics space," said Jeff Liter, President and CEO of B-MoGen. "CytoSen's innovation, science and pioneering technology is a perfect fit with B-MoGen's genome engineering experience and technology."
Both companies are experiencing rapid growth by providing cutting edge science and technical know-how to help create life-changing human disease therapies. This partnership looks to enable the creation and delivery of new NK cell therapies for cancer patients.